Background: Statin treatment in association with physical exercise can substantially reduce mortality in dyslipidaemic individuals. However, the available data to compare the efficacy and safety of statins and exercise combination therapy with statin monotherapy are limited. Design: Systematic review and meta-analysis. Methods: We systematically searched PubMed, Embase and the Cochrane Library from database inception until December 2016. We included randomised and non-randomised studies that compared the efficacy and safety of statins and exercise combination therapy with statin monotherapy in patients with dyslipidaemia. Standardised mean differences were calculated and pooled by means of fixed effects models. The risk of bias and heterogeneity among trials was also assessed. Seven articles were assessed in terms of the efficacy of therapy and 13 from the viewpoint of therapeutic safety. Results: In terms of efficacy, statins and exercise combination decreased the incidence of diabetes mellitus, improved insulin sensitivity and inflammation, but caused no change in lipid profile compared to statins alone. In terms of safety, statins and exercise combination increased peak oxygen uptake (standardised mean difference 1.01, 95% confidence interval 0.46 to 1.57) compared to statins alone. In contrast to statin-induced myopathy, chronic exercise training prior to statin treatment could counteract statin-induced adverse effects in skeletal muscle. Conclusion: Statins and exercise combination therapy is more effective than statin monotherapy in terms of insulin sensitivity, inflammation and exercise capacity. The small number of studies warrants the need for more randomised controlled trials evaluating the efficacy and safety of combination therapy.
Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are the most effective and most frequently prescribed medications to decrease lowdensity lipoprotein (LDL) cholesterol levels. Every 1 mmol/L reduction in LDL cholesterol is associated with 10-20% reduction in the risk of cardiovascular events and all-cause mortality. 1 However, other than the beneficial outcomes, statins also produce adverse effects in certain users, including an increased risk of diabetes, elevated liver enzyme levels and myopathy.
Exercise prevents or manages a wide range of health problems, including type 2 diabetes mellitus, metabolic syndrome, obesity, stroke, depression and certain cancers. 2, 3 Moreover, epidemiological studies have shown that exercise is associated with markedly decreased morbidity and mortality in cardiovascular diseases. 4 The 2008 Physical Activity Guidelines Advisory Committee report recommended about 150 minutes/week of moderate intensity physical activity or 75 minutes/week of vigorous intensity aerobic exercise. 5 Therefore, the combination of statins and exercise should be recommended. However, the comparative efficacy of statins and exercise combination therapy and statin monotherapy has not yet been evaluated in detail. The safety of combination therapies remains controversial.
Thus, in the present meta-analysis, we reviewed changes in lipid profiles, insulin sensitivity, inflammation and adverse effects after exercise in patients treated with statins. We integrated efficacy and safety data. The aim of our work was to highlight the advantages and disadvantages of statins and exercise combination, used to treat patients with dyslipidaemia.
Methods

Data sources and searches
We selected relevant studies published from their inception date until December 2016, by searching PubMed, Embase and Cochrane. We applied no language restrictions. Searches were limited to randomised controlled trials (RCTs), non-RCTs or randomised trials performed in humans or mammalians. The latter two types of trials were defined as prospective trials with a comparison group. We used the following combined text and MeSH terms: 'statin' and 'exercise'. The complete search used for PubMed was: (((((((((((((((((((Hydroxymethylglutaryl We considered all potentially eligible studies for review, irrespective of the primary outcome or language. We also carried out a manual search, using the reference lists of key articles published in English.
Study selection
Two authors (JYC and YTW) independently reviewed and selected studies to be evaluated. The inclusion criteria were: (a) the work was RCTs, non-RCTs or randomised tirals performed in humans or mammalians that (b) compared the efficacy and safety of the combination of statins and exercise therapy, (c) included measurements of mortality, lipid profiles, insulin sensitivity, inflammation and (d) described liver and muscle-related adverse effects. Any disagreement in terms of the inclusion of an article for evaluation was resolved by consensus (attained by discussion) with a third investigator (JHH). 
Data extraction and data synthesis
Assessment of study quality
We used the Cochrane risk of bias tool to assess the quality of the studies. 6 The tool consists of the following seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and 'other bias'. Each domain was considered for each of the included studies and assigned either a low, high or unclear risk of bias. For each of the included studies an overall risk was displayed visually utilising RevMan 5.3 software.
Data analysis
Statistical heterogeneity between studies was tested with the Q statistic and quantified with the I 2 statistic.
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A fixed-effects model was used in the analysis. 8 Sensitivity analyses were performed by excluding, in turn, the contribution of each study to the meta-analysis data. We visually inspected funnel plots of the study size versus standard error and performed Egger's regression asymmetry test to assess bias due to small study effects. 9 There was no indication of small study effects from the funnel plots or Egger's test.
This systematic review was planned, conducted and reported based on the guidelines set out by the preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA). 10 Statistical analyses were carried out using RevMan 5.3.
Results
Study selection and characteristics
The search strategy identified 594 studies. After the removal of duplicates, 476 were broadly screened by title and abstract and 428 articles were excluded. Forty-five were included for full text review. Of these, a further 41 were excluded leaving four articles for inclusion in the meta-analysis. The reasons for excluding articles are shown in Figure 1 ; eight papers did not report on the outcomes of interest. The characteristics of included studies are shown in Tables 1 and 2 .
Safety analysis
Mortality and other clinical outcomes. A recent study found that, in patients with dyslipidaemia, the combination of statins and exercise was effective for reducing the risk of all-cause mortality. 11 Mortality risk was lower in the combination therapy than either alone. No trials comparing combination therapy with statin monotherapy reported the occurrence of stroke, myocardial infarction (MI), transient ischaemic attacks, or revascularisation procedures in patients with statin therapy.
Total cholesterol. In total, three studies assessed changes in total cholesterol in 164 patients treated with statins alone and 66 treated with a combination of statins and exercise (Figure 2(a) ). There were no significant differences in total cholesterol levels between the two groups (standard mean difference (SMD) -0.23, 95% confidence interval (CI) -0.53 to 0.06, I
2 ¼ 0%). Data re-analysis using a random-effects model also revealed no between-treatment difference.
LDL cholesterol. In total, three studies assessed changes in LDL cholesterol in 164 patients treated with statins alone and 66 treated with a combination of statins and exercise ( Figure 2(b) ). There were no significant differences in LDL cholesterol levels between the two groups (SMD -0.29, 95% CI -0.58 to 0.00, I 2 ¼ 0%). Data reanalysis using a random-effects model also revealed no between-treatment difference.
HDL cholesterol. In total, three studies assessed changes in high-density lipoprotein (HDL) cholesterol in 164 patients treated with statins alone and 66 treated with a combination of statins and exercise (Figure 2(c) ). There were no significant differences in HDL cholesterol levels between the two groups (SMD 0.12, 95% CI -0.18 to 0.41, I
Triglycerides. In total, three studies assessed changes in triglyceride levels in 164 patients treated with statins alone and 66 treated with a combination of statins and exercise (Figure 2(d) ). There were no significant differences in triglyceride levels between the two groups (SMD -0.18, 95% CI -0.47 to 0.11, I
2 ¼ 0%)). Data re-analysis using a random-effects model also revealed no between-treatment difference.
Diabetes mellitus. One trial of 8853 participants assessed the effect of cardiorespiratory fitness on the incidence of diabetes in healthy volunteers with the initiation of statin therapy. 15 There was an increased rate of diabetes development in the low fit group compared with the moderate/high fit group.
Two trials comparing combination therapy with statin monotherapy reported changes in insulin sensitivity in type 2 diabetes mellitus patients treated with statins. 13, 16 One trial reported decreased insulin sensitivity after a bout of exercise in patients with statins. 16 However, another trial of 36 participants found a significantly increase in insulin sensitivity (þ72%) after chronic exercise as compared to pre-training levels in patients with statins.
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Inflammation. In total, three studies assessed changes in C-reactive protein (CRP), but no study could be included in the meta-analysis because of the limited original data. Meex et al. 13 found that there were no differences between pre-exercise and post-exercise in the serum CRP level in patients treated with statins. However, Coen et al. 17 demonstrated that the addition of exercise training to rosuvastatin treatment further lowered CRP. This result suggested an additive antiinflammatory effect of exercise. Furthermore, Konig et al. 14 found that there was a reduction in serum CRP in patients with a high level of physical exercise and taking statins compared to those patients with a low level of physical exercise and taking statins.
Safety analysis
Liver-related adverse effects. One study described adverse hepatic events. Coen et al. 24 demonstrated that adding exercise to rosuvastatin treatment (10 mg/day for 20 weeks) did not normalise alanine aminotransferase (ALT) levels as compared with rosuvastatin treatment alone. The authors found no difference in serum ALT in combination therapy compared with statin monotherapy. Given the limited amount of data, more research is needed in order to confirm this.
Muscle-related adverse effects. The kinds of musclerelated adverse effects were myalgia, myopathy with elevated creatine kinase (CK) with or without symptoms, rhabdomyolysis, decreased muscle mass and strength. The detailed results of human and rodent studies that combined statins with physical exercise on skeletal muscle are listed in Table 2 . A meta-analysis was not performed due to the high heterogeneity of intervention types and outcome variables among the studies.
Thirteen studies evaluating the effects of statins in association with acute or chronic exercise on muscle were analysed. 13, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Study results indicated that intense training performed by patients or athletes, as well as the practice of acute eccentric and strenuous exercise, might exacerbate muscle injury resulting from the administration of statins. On the other hand, chronic exercise of moderate intensity, performed prior to statin treatment, could attenuate the harmful effects and improve muscle function in its practitioners.
This review also focused on the effects of combination therapy on exercise capacity. In total, three studies assessed changes in peak oxygen uptake (VO 2peak ); 12,13,24 a total of 29 patients treated with statins alone and 29 treated with a combination of statins and exercise (Figure 3) . The combination therapy increased VO 2peak compared to statin monotherapy (SMD 1.01, 95% CI 0.46 to 1.57, I
2 ¼ 0%). Data reanalysis using a random-effects model also revealed no between-treatment difference. 
Sensitivity analyses
Sensitivity analysis was conducted by recalculating all findings after data from each study included in the meta-analysis were omitted in turn. The findings were not significantly altered through this method. Figure 4 showed the risk of bias for each study according to the seven domains in the Cochrane risk of bias tool. Our attempts to assess risk of bias were limited in many cases by incomplete reporting by authors. The risk of bias was most commonly seen due to a lack of blinding of participants and personnel, which was difficult to manage in an exercise intervention study because exercise must be supervised.
Study quality
Discussion
We performed the present meta-analysis to evaluate the efficacy and safety of statins and exercise combination prescribed for patients with dyslipidaemia. First, compared with statin monotherapy, statins and exercise combination therapy could yield improved insulin sensitivity, inflammation and exercise capacity, but no change in lipid concentrations. Second, our results showed that chronic exercise training, but not acute exercise, could counteract statin-induced adverse effects in skeletal muscle. We found no benefit of combination therapy over statin monotherapy in terms of MI, stroke, and revascularisation procedures in patients receiving statin therapy. Most studies were short, which limited their ability to detect potential differences in important clinical outcomes. Assessment of these outcomes required large long-term trials.
It was unexpected that the addition of exercise to statin therapy did not cause an improvement in the lipid profile. Our results were in line with the study of Coen et al., 24 which demonstrated that adding exercise to rosuvastatin treatment lowered oxidatively modified LDL more than rosuvastatin alone, but had no effect on HDL cholesterol and LDL cholesterol. In contrast to our results, Panayiotou et al. 16 found improved lipid profiles after eccentric exercise bouts in patients treated with statins. Furthermore, Tani et al. 28 suggested that the combination of statins and exercise therapy could result in coronary plaque regression due to the increased serum HDL cholesterol.
Statin use was associated with several muscle-related adverse effects, including myalgia, myopathy with elevated CK, rhabdomyolysis, decreased muscle mass and strength. 29, 30 Many clinical studies have described muscle adverse effects associated with statin monotherapy or the combination of statins and exercise therapy. [31] [32] [33] [34] [35] Our present safety analysis showed that acute exercise might exacerbate statin-induced muscle complaints in patients with statins, whereas moderate physical training prior to statin treatment could counteract statin-induced adverse effects in skeletal muscle. Therefore, when treating dyslipidaemic patients undergoing statin treatment, it was suggested that they should undertake about three days per week of moderate intensity aerobic physical activity combined with resistance exercise. The provision of physical training prior to drug administration was desirable. 33 When treating patients who performed exercise training and confirmed statin myalgia, clinicians have several therapeutic options: 32 adjusting statin therapy by changing the type of statin, decreasing the dose of statin, utilising a hydrophilic statin, recommending a drug holiday followed by a re-challenge, or decreasing the intensity and duration of exercise training. Keen attention should also be given to avoiding drug interactions.
Statin use could also directly compromise aerobic exercise capacity. However, the current systematic review and meta-analysis indicated that adding exercise to statins could increase VO 2peak compared to statin monotherapy. VO 2peak was an important clinical measure in patients with cardiac rehabilitation as it was closely linked to cardiovascular mortality. 36 Increasing VO 2peak was a key objective of cardiac rehabilitation. Current results favour adding exercise to statin treatment to improve exercise capacity, thus decreasing morbidity and mortality in cardiovascular diseases.
Limitations
Our present meta-analysis has some limitations, which mainly reflect the lack of high quality research in the field to date. The first limitation was the small number of relevant studies, generally with a small number of participants. Second, we performed no grey literature search, and thus cannot guarantee that there was no publication bias. Third, we used the Cochrane risk of bias tool to assess the risk of bias from individual studies. However, it was limited by the information presented by the individual paper. Fourth, original data were sparse and the works reviewed differed in terms of dosage regimens and study design. Finally, the quality of studies we included was low to moderate, which indicated the need for further well-designed RCTs in this field.
Conclusions
Despite these limitations, this is the first study (to our knowledge) to compare the efficacy and safety of statins and exercise combination therapy to that of statin monotherapy in patients with dyslipidaemia. The current evidence supported the use of combination therapies over monotherapy, including insulin sensitivity, inflammation and exercise capacity. However, these results were insufficient to guide many clinical decisions. Furthermore, safety issues, especially musclerelated side effects, require careful consideration. The benefits of combination therapy need to be clearly defined along with the attendant risks before widespread use of combination treatments can be advocated.
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